WallStreetZenWallStreetZen

NASDAQ: HUMA
Humacyte Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for HUMA

Based on 2 analysts offering 12 month price targets for Humacyte Inc.
Min Forecast
$6.00+104.08%
Avg Forecast
$11.00+274.15%
Max Forecast
$16.00+444.22%

Should I buy or sell HUMA stock?

Based on 2 analysts offering ratings for Humacyte Inc.
Strong Buy
Strong Buy
2 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their HUMA stock forecasts and price targets.

HUMA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Cantor Fitzgerald
Top 4%
97
Strong BuyReiterates$6.00+104.08%2023-08-31
Benchmark
Bottom 6%
6
Strong BuyReiterates$16.00+444.22%2023-08-15

1 of 1

Forecast return on equity

Is HUMA forecast to generate an efficient return?
Company
-192.93%
Industry
30.61%
Market
58.41%
HUMA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is HUMA forecast to generate an efficient return on assets?
Company
-70.14%
Industry
12.11%
HUMA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

HUMA revenue growth forecast

How is HUMA forecast to perform vs Biotechnology companies and vs the US market?
Company
3,100.52%
Industry
60.6%
Market
7.96%
HUMA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
HUMA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

HUMA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
HUMA$2.94$11.00+274.15%Strong Buy
INZY$4.90$15.00+206.12%Strong Buy
EYPT$8.57$32.20+275.73%Strong Buy
GLUE$5.98$11.00+83.95%Hold
APLM$3.60$21.50+497.22%Strong Buy
View Top Biotech Stocks

Humacyte Stock Forecast FAQ

Is Humacyte Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: HUMA) stock is to Strong Buy HUMA stock.

Out of 2 analysts, 2 (100%) are recommending HUMA as a Strong Buy, 0 (0%) are recommending HUMA as a Buy, 0 (0%) are recommending HUMA as a Hold, 0 (0%) are recommending HUMA as a Sell, and 0 (0%) are recommending HUMA as a Strong Sell.

If you're new to stock investing, here's how to buy Humacyte stock.

What is HUMA's forecast return on equity (ROE) for 2023-2025?

(NASDAQ: HUMA) forecast ROE is -192.93%, which is considered weak.

What is HUMA's Price Target?

According to 2 Wall Street analysts that have issued a 1 year HUMA price target, the average HUMA price target is $11.00, with the highest HUMA stock price forecast at $16.00 and the lowest HUMA stock price forecast at $6.00.

On average, Wall Street analysts predict that Humacyte's share price could reach $11.00 by Aug 31, 2024. The average Humacyte stock price prediction forecasts a potential upside of 274.15% from the current HUMA share price of $2.94.

What is HUMA's forecast return on assets (ROA) for 2023-2025?

(NASDAQ: HUMA) forecast ROA is -70.14%, which is lower than the forecast US Biotechnology industry average of 12.11%.
©2023 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.